Edward Garmey, M.D.
Chief Medical Officer and Senior Vice President
Prior to joining Cerulean, Dr. Garmey served as Vice President for Clinical Development at ArQule, Inc., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Edward additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Edward was Medical Director at GPC Biotech, where he helped oversee global clinical development studies.
A pediatric hematologist-oncologist by training, Edward is a graduate of Harvard and New York Universities and completed his medical training at Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and the Memorial Sloan-Kettering Cancer Center. Edward completed additional research fellowships at the National Institutes of Health and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana. A recipient of young investigators awards from the American Society of Hematology and the American Heart Association, Edward has presented at numerous international conferences and is an author on over 30 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund and serves there as an advisor to the fund’s $1.25 Million “BioAccelerate NYC Prize” for biomedical research. In Boston, Edward is a member of the Scientific Advisory Board for the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative and he additionally serves on the board of visitors of Hearth, a Boston-based non-profit organization dedicated to the elimination of homelessness among the elderly.